Streetbeat News

Stock Prices

SDIG

Stronghold Digital Mining (NASDAQ:SDIG) reported Q3 sales of $17.73M, missing the analyst consensus estimate of $24.06M by 26.32%. This represents a 28.37% decrease from the $24.75M in sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:04 pm

JAGX

Jaguar Health (NASDAQ:JAGX) reported Q3 GAAP EPS of $(0.38), surpassing the $(1.23) estimate, and sales of $2.81M, exceeding the $2.46M estimate. This reflects a significant reduction in losses and a slight decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:03 pm

OCEA

Ocean Biomedical presented preclinical oncology data for VRON-0300 at the SITC 2023 Annual Meeting. The data could be significant for the company's cancer treatment pipeline.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:03 pm

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) reported a significant improvement in Q3 2023 with a 99.5% decrease in losses per share to $(0.13) from $(25.95) YoY. Sales also increased by 32.37% to $5.19M from $3.92M YoY.

Portfolio Pulse from totan@benzinga.com

November 14, 2023 | 1:02 pm

NVDA

Nvidia Corp. (NASDAQ:NVDA) is poised to extend its rally to a 10th consecutive session, with shares trading up in premarket on Tuesday. The stock's recent gains have been driven by optimism around artificial intelligence and the unveiling of new AI chips, the H200. Nvidia's performance has made it the top S&P 500 stock this year and a leader among major tech stocks. The company is set to report Q3 results on November 21, which could further influence the stock's trajectory.

Portfolio Pulse from Shanthi Rexaline

November 14, 2023 | 1:01 pm

TMO

Thermo Fisher Scientific has authorized a new $4 billion share repurchase program. This move is part of the company's capital allocation strategy and reflects its commitment to returning value to shareholders. The repurchase authorization does not have an expiration date and can be executed through open market purchases or privately negotiated transactions.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:01 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target for ACRS is $29.43, which is a significant increase from the previous target of $18.00. The high target is $43.00 and the low is $2.00. The increase in the average price target suggests a positive outlook from analysts.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

UEC

Uranium Energy (AMEX:UEC) has received positive ratings from analysts in the last quarter, with 3 bullish and 1 somewhat bullish rating. The average price target is $7.25, which is higher than the current price of $5.94, indicating a potential upside. The average price target has increased by 3.57% from the previous target of $7.00. Analysts typically review stocks each quarter and their ratings are based on company performance, financial statements, and insider communications.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

MBCN

Middlefield Banc Corp. (NASDAQ:MBCN) has appointed Ronald L. Zimmerly, Jr. as its new CEO, effective January 1, 2024. He will succeed James R. Heslop, II, who is retiring. Zimmerly is currently the President and Director of Middlefield and The Middlefield Banking Company. Heslop will also resign from the Board of Directors on December 31, 2023, and the Board will be reduced from 13 to 12 members.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:00 pm

AKRO

11 Wall Street analysts have recently provided their opinions on Akero Therapeutics (NASDAQ:AKRO), with an average price target of $52.27, which is significantly higher than the current price of $13.95. The consensus among these analysts is positive, with 4 bullish and 7 somewhat bullish ratings. However, this target represents an 18.15% decrease from the previous target of $63.86. Analysts' ratings are based on comprehensive analysis, including company data and industry trends.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm